For patients with active PsA and comorbid diabetes who are treatment naïve to OSMs and biologic therapies, the recommended therapy is:
b. an OSM other than MTX
c. an IL-17i biologic
d. a TNFi biologic
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.